Ranbaxy gets USFDA nod for Doxycycline Tablets
Ranbaxy Laboratories Ltd has received approval from USFDA for manufacturing and marketing Doxycycline Tablets in the US market.
By PTI |
MUMBAI: Ranbaxy Laboratories Ltd has received approval from USFDA for manufacturing and marketing Doxycycline Tablets in the US market.
The company informed the Bombay Stock Exchange that it got the approval for marketing the antibiotic in strengths of 50mg, 75mg and 100mg.
Doxycycline is indicated for a variety of infections caused by susceptible strains or micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, it added.
The USFDA's office of generic drugs, has determined the company's formulations to be bioequivalent and having the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co, Ranbaxy added.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
